{
  "door_code": "H03GENERIC_PHARMA",
  "semantic_path": "HEALTH.PHARMACOLOGY.MANUFACTURING",
  "aliases": [
    "generic drugs",
    "indian pharma",
    "bioequivalence",
    "drug manufacturing"
  ],
  "context_bundle": {
    "summary": "Generic drug manufacturing differences - India CDSCO vs FDA regulations, bioequivalence requirements, excipient formulations, crystal polymorphism affecting drug performance.",
    "prerequisites": [],
    "related_doors": [
      "H01ARMODAFINIL",
      "H02PHARMACOKINETICS"
    ],
    "onboarding": {
      "quick_start": "India CDSCO doesn't require bioequivalence studies that FDA mandates. Same molecule can have +/-20% bioavailability variance legally. Excipient ratios, granulation methods, compression force are trade secrets affecting dissolution.",
      "full_context_path": "",
      "common_patterns": [
        "Crystal polymorphs = same chemical different physical properties",
        "Wet vs dry granulation affects release profile",
        "Coating thickness changes absorption timing"
      ],
      "known_errors": [
        "Indian generics not FDA approved - wider variance allowed",
        "Excipient list public but ratios proprietary",
        "No published peer-reviewed comparisons of Indian generics"
      ]
    },
    "resources": {
      "docs": [],
      "code": [],
      "tests": [],
      "errors": []
    },
    "metadata": {
      "last_updated": "2025-11-29T16:36:42.051304+11:00",
      "confidence": 1.0,
      "tags": [
        "generics",
        "fda",
        "cdsco",
        "india",
        "bioequivalence",
        "excipients",
        "polymorphism",
        "manufacturing"
      ],
      "category": "SECURITY",
      "subcategory": "PHARMACOLOGY",
      "version": "1.0.0",
      "agent_affinity": [],
      "size_bytes": 1810,
      "token_estimate": 453.0
    }
  }
}
